Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Definition of the accelerated phase of chronic myelogenous leukemia.

Literature DB >> 3422090

Definition of the accelerated phase of chronic myelogenous leukemia.

H M Kantarjian, M Talpaz.

Abstract

Entities: Disease

Mesh：

Year: 1988 PMID： 3422090 DOI： 10.1200/JCO.1988.6.1.180

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. Upregulating miR-146a by physcion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells.

Authors: Wenjun Liu; Juan He; Yiling Yang; Qulian Guo; Fei Gao
Journal: Am J Cancer Res Date: 2016-11-01 Impact factor: 6.166

2. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors: Constantine S Tam; Hagop Kantarjian; Jorge Cortes; Alice Lynn; Sherry Pierce; Lingsha Zhou; Michael J Keating; Deborah A Thomas; Srdan Verstovsek
Journal: J Clin Oncol Date: 2009-09-28 Impact factor: 44.544

3. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

Authors: Ellen Weisberg; Laurie Catley; Renee D Wright; Daisy Moreno; Lolita Banerji; Arghya Ray; Paul W Manley; Juergen Mestan; Doriano Fabbro; Jingrui Jiang; Elizabeth Hall-Meyers; Linda Callahan; Jamie L DellaGatta; Andrew L Kung; James D Griffin
Journal: Blood Date: 2006-10-26 Impact factor: 22.113

Definition of the accelerated phase of chronic myelogenous leukemia.

1. Upregulating miR-146a by physcion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells.

2. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

3. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

Review 4. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.

Review 5. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

6. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.

Review 7. Treatment selection after imatinib resistance in chronic myeloid leukemia.